Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Perry Elliott

Showing results (81-90 of 156) with videos related to

Pageof 16
Sort By:
Heart (British Cardiac Society)|May 29, 2016
Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysisRui Providencia, Perry Elliott, Kiran Patel, et al.
Circulation. Heart Failure|June 15, 2017
Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)Mathew S Maurer, Perry Elliott, Giampaolo Merlini, et al.
Heart Failure Reviews|October 17, 2023
Electrocardiographic abnormalities in patients with cardiomyopathiesAlberto Aimo, Agnese Milandri, Andrea Barison, et al.
European Journal of Heart Failure|July 9, 2020
An expert consensus document on the management of cardiovascular manifestations of Fabry diseaseAleš Linhart, Dominique P Germain, Iacopo Olivotto, et al.
European Heart Journal|November 20, 2012
Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and CanadaAnnika F M Haywood, Nancy D Merner, Kathy A Hodgkinson, et al.
ESC Heart Failure|October 13, 2025
Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CMPablo Garcia-Pavia, Francisco Javier Haro Del Moral, Francesco Cappelli, et al.
Circulation. Heart Failure|December 20, 2021
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid CardiomyopathyPerry Elliott, Brian M Drachman, Stephen S Gottlieb, et al.
Circulation|October 6, 2010
Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathyKhalid Abozguia, Perry Elliott, William McKenna, et al.
Future Cardiology|January 30, 2023
Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language SummaryPerry Elliott, Brian M Drachman, Stephen S Gottlieb, et al.
International Journal of Cardiology|February 11, 2015
Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophyAndrew S Flett, Viviana Maestrini, Don Milliken, et al.
Pageof 16

Showing results (81-90 of 156) with videos related to

Sort By:
Pageof 16
Heart (British Cardiac Society)|May 29, 2016
Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysisRui Providencia, Perry Elliott, Kiran Patel, et al.
Circulation. Heart Failure|June 15, 2017
Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)Mathew S Maurer, Perry Elliott, Giampaolo Merlini, et al.
Heart Failure Reviews|October 17, 2023
Electrocardiographic abnormalities in patients with cardiomyopathiesAlberto Aimo, Agnese Milandri, Andrea Barison, et al.
European Journal of Heart Failure|July 9, 2020
An expert consensus document on the management of cardiovascular manifestations of Fabry diseaseAleš Linhart, Dominique P Germain, Iacopo Olivotto, et al.
European Heart Journal|November 20, 2012
Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and CanadaAnnika F M Haywood, Nancy D Merner, Kathy A Hodgkinson, et al.
ESC Heart Failure|October 13, 2025
Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CMPablo Garcia-Pavia, Francisco Javier Haro Del Moral, Francesco Cappelli, et al.
Circulation. Heart Failure|December 20, 2021
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid CardiomyopathyPerry Elliott, Brian M Drachman, Stephen S Gottlieb, et al.
Circulation|October 6, 2010
Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathyKhalid Abozguia, Perry Elliott, William McKenna, et al.
Future Cardiology|January 30, 2023
Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language SummaryPerry Elliott, Brian M Drachman, Stephen S Gottlieb, et al.
International Journal of Cardiology|February 11, 2015
Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophyAndrew S Flett, Viviana Maestrini, Don Milliken, et al.
Pageof 16